Although our laboratory data were collected from patients with metastatic breast cancer, there is no a priori reason to think that the results would be different for patients treated with CDK4/6is for breast cancer in the adjuvant setting or even for patients treated for other malignancies. This evidence concerns the gene CDK4 and breast cancer.